Machine learning improves adequacy assessment during rapid onsite evaluation in lung cancer, suggesting enhanced diagnostic accuracy.
Lung cancer is projected to become the leading cause of cancer-related mortality in both smoking and non-smoking populations. Rapid onsite evaluation (ROSE) of fine-needle aspiration specimens is essential for timely diagnosis and procedural decision-making during lung cancer assessment. We developed a machine-learning pipeline for cell-based adequacy assessment and lesion detection that integrates automated cell detection, convolutional neural network-based cell classification, and slide-level aggregation using a random forest model. On held-out test data, binary classifiers for lymphocytes and tumor cells achieved accuracies of 91.5% and 92.7% with recalls of 92.6% and 93.1%, respectively. The end-to-end ROSE system demonstrated class accuracies of 82-85%, comparable to human cytologist performance, and a lesion-focused classifier reached a recall of 92.0%. These findings indicate that machine-learning-based cell analysis can support ROSE by expediting adequacy assessment and improving diagnostic yield during TBNA procedures.
No takes yet. Share an insight, caveat, or question.
Brechenmacher et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: